

**Supplementary Table 1.** Neutralizing antibody responses of patients receiving BNT162b2 (n=228)

	MAFLD (n=59)	Control (n=168)	P-value
Seroconversion rate*			
D21	42/59 (71.2)	128/167 <sup>†</sup> (76.6)	0.442
D56	59/59 (100.0)	168/168 (100.0)	1.000
D180	40/40 <sup>†</sup> (100.0)	116/117 <sup>†</sup> (99.1)	1.000
Highest-tier response rate <sup>‡</sup>			
D56 Highest-tier response rate	3/59 (5.1)	26/168 (15.5)	0.037
D180 Highest-tier response rate	0/40 (0.0)	3/117 (2.6)	0.570
vMN GMT			
D21	13.3 (10.7–16.4)	13.3 (11.8–15.0)	0.841
D56	92.1 (75.9–111.1)	101.4 (88.2–115.6)	0.675
D180	39.3 (31.8–48.9)	41.0 (35.2–47.5)	1.000

vMN GMT is presented as mean (95% confidence interval).

MAFLD, metabolic-associated fatty liver disease; D21, day21; D56, day56; D180, day180; vMN GMT, virus microneutralization geometric mean titer.

\*Seroconversion rate is considered as positive if vMN titer  $\geq 10$ .

<sup>†</sup>Subjects with missing data are excluded.

<sup>‡</sup>Highest-tier response is defined as vMN titer  $> 160$ .